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Abstract
In many healthcare settings, benchmarking for complex procedures has become a mandatory requirement by competent
authorities, regulators, payers and patients to assure clinical performance, cost-effectiveness and safe care of patients. In
several countries inside and outside Europe, benchmarking systems have been established for haematopoietic stem cell
transplantation (HSCT), but access is not universal. As benchmarking is now integrated into the FACT-JACIE standards, the
EBMT and JACIE established a Clinical Outcomes Group (COG) to develop and introduce a universal system accessible
across EBMT members. Established systems from seven European countries (United Kingdom, Italy, Belgium, France,
Germany, Spain, Switzerland), USA and Australia were appraised, revealing similarities in process, but wide variations in
selection criteria and statistical methods. In tandem, the COG developed the ﬁrst phase of a bespoke risk-adapted
international benchmarking model for one-year survival following allogeneic and autologous HSCT based on current
capabilities within the EBMT registry core dataset. Data completeness, which has a critical impact on validity of centre
comparisons, is also assessed. Ongoing development will include further scientiﬁc validation of the model, incorporation of
further variables (when appropriate) alongside implementation of systems for clinically meaningful interpretation and
governance aiming to maximise acceptance to centres, clinicians, payers and patients across EBMT.
Introduction, aims and objectives
The complexity of modern medicine and demands in health-
care for accountability, transparency, cost-effectiveness and
quality improvement requires deﬁnition of quality of care.
Stakeholders, including specialist and referring clinicians,
public health bodies, patients and families wish to understand
the differences in survival and other patient outcomes across
centres. Benchmarking, deﬁned as “the process of comparing
a practice’s performance with an external standard”
* John A. Snowden
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(https://www.ahrq.gov/professionals/prevention-chronic-care/
improve/system/pfhandbook/mod7.html. Accessed 31/05/
2019), aims to provide a means of comparing clinical per-
formance with the wider dataset. Benchmarking has become
mandatory in a number of countries for a range of medical and
surgical procedures and is used by competent authorities,
regulators and payers for quality assurance of clinical effec-
tiveness, safety and cost-effectiveness of patient care [1–7].
However, there are challenges in the delivery of benchmark-
ing, particularly in deﬁning a fair, accurate and clinically
meaningful methodology acceptable to all stakeholders
underpinned by a reliable and complete source of clinical
outcomes data. For long-term sustainability, there is also a
need for evidence of sufﬁcient impact on patient outcomes to
justify the considerable time and resources invested [7].
Haematopoietic stem cell transplantation (HSCT) is a
high-risk treatment which requires a multi-disciplinary
approach and often complex interactions with different
teams and services [8]. Risks are dependent on the type of
transplant procedure, and also patient-related and disease-
related factors, and patients may be consented for levels of
treatment-related mortality risk from around 1% to higher
than 30%, and balanced against the outcomes with other
non-transplant treatments [8–13]. The procedure-related
risks are highest in the ﬁrst year but frequently persist
for several years following transplant, reﬂecting the
profound immune suppression and other chronic compli-
cations associated with some HSCT procedures. Relapse
is also a feature of the post-transplant pathway and, to
a degree, reﬂects the patient selection and transplant
technique [13].
External quality review of HSCT centres through
accreditation by FACT-JACIE standards has become
established over the last two decades and its adoption is
associated with improved survival outcomes, especially in
allogeneic HSCT [14, 15]. Benchmarking has been inte-
grated into the FACT-JACIE quality management standards
since the 6th edition in 2015 [16], which included the
standard B4.7.5: The Clinical Programme should achieve
one-year survival outcome within or above the expected
range when compared to national or international outcome
data (FACT-JACIE International Standards for Hemato-
poietic Cellular Therapy Product Collection, Processing and
Administration, 6th edition March 2015). The 7th edition,
published in 2018, has developed this further under stan-
dard B4.7.6 mandating benchmarks for non-relapse mor-
tality at 100 days (FACT-JACIE International Standards for
Hematopoietic Cellular Therapy Product Collection, Pro-
cessing and Administration, 7th edition March 2018).
In several countries inside and outside Europe bench-
marking systems for HSCT outcomes have been established
[17, 18]. However, the extent and methodologies of
benchmarking across EBMT national members have not
previously been critically appraised. Access to a nationally
based benchmarking system is not universal across EBMT
and it may be unfeasible, even meaningless, in small
countries with limited centres and populations.
Therefore, there is a signiﬁcant unmet need for a con-
sistent system, open to all EBMT member centres, to
benchmark survival outcomes against national and/or
international norms. Given the impact of pre-transplant
variables on outcome of HSCT, risk status needs to be
adequately incorporated into benchmarking methodology
[18–21], otherwise individual centres, or even national
HSCT communities, may be reluctant to accept the validity
of results, particularly if they indicate relative centre (or
national) underperformance. Importantly, there should also
be no deterrent to treating high-risk patients based on
concerns that overall centre performance may be affected.
Systems will be essential to advising centres appropriately
how to address and correct underperformance.
The upgrading of the EBMT registry, now with over
660,000 HSCT registrations, from the ProMISe system to
the new MACRO platform, has provided an opportunity by
which survival outcomes benchmarking could be addressed
across the EBMT membership. The development of
benchmarking was therefore integrated as a ‘work package’
within the broader ‘Project 2020’ registry upgrade via
Clinical Outcomes Group (COG). The ‘work package’
scoped existing national benchmarking systems, both within
and outside of EBMT, to inform the development of sta-
tistical methodology for a universally available risk-adapted
benchmarking system, to be ultimately operated within the
new MACRO-based registry and overseen by JACIE. This
review summarises the ﬁrst stage (or ‘ﬁrst phase’) in a
longer-term development of a fair, acceptable and sustain-
ably delivered international benchmarking system across
the diverse health services and cultures within EBMT.
Methods
As an intrinsic part of the EBMT registry upgrade ‘Project
2020’, a work package “Clinical quality assurance of
patient survival outcomes by international benchmarking”
was incorporated. Following initial discussions within
meetings of the EBMT Board and EBMT Annual Meeting
in Marseille in 2017–18, the Leiden University Medical
Centre (LUMC) team was appointed to develop statistical
methodology for benchmarking for the EBMT. Subse-
quently, a multi-national group of senior HSCT clinicians,
registry managers, EBMT (including JACIE) staff and
biostatisticians from LUMC, EBMT Patient Advocacy
Committee and national societies met systematically as the
‘Clinical Outcomes Group’ on a monthly basis from the
Lisbon Annual Meeting in March 2018–June 2019.
J. A. Snowden et al.
CIBMTR and Australasian (ABMTRR) representatives
were co-opted in order to access their experience. After
agreeing Terms of Reference, discussions progressed either
by e-mail or teleconference with periodic in-person meet-
ings (see Fig. 1). Statistical aspects were led by the
Department of Biomedical Data Sciences, LUMC with
input from the EBMT Statistical Committee and national
statistical representatives. Data was sourced from the
EBMT registry which is supported by mandatory reporting
of anonymised data from routinely consented patients by
full EBMT centre members, and supplemented with data
from the broader EBMT activity survey. The introductory
phase of the benchmarking system and plans for develop-
ment were ﬁnalised and ratiﬁed at the EBMT Board meet-
ing in June 2019.
National HSCT organisations providing existing bench-
marking systems were identiﬁed and representatives were
approached to join the extended membership of the Clinical
Outcomes Group and contribute information that characterised
the individual approaches to benchmarking. A survey was sent
out to the representatives to characterise their processes, which
are summarised in Tables 1–3. Also, information about how
results are presented to the participating centres, and examples
of plots and tables were requested.
Tables 1–3 summarise and compare the different approa-
ches. To accompany the tabulated information, summaries of
each national approach to benchmarking are provided in the
Supplementary Information part 1. The processes, member-
ship and roles within the Clinical Outcomes Group are
summarised in Supplementary Information part 2.
Development of a ‘ﬁrst phase’ statistical model for
benchmarking of 1-year survival across EBMT
centres
The initial work focused on constructing case-mix-corrected
funnel plots, a well-known tool for performance evaluation,
to compare centres to the national or European average
performance with respect to 1-year overall survival. The
benchmarking mechanisms considered a series of risk fac-
tors (“case mix” variables) to be integrated into the statis-
tical models to allow for a fair comparison of centres related
to different patient population characteristics. The output
was to be a risk-adjusted comparison of each centre with the
internal benchmark, set by the average across participating
EBMT centres.
As part of the early development work, the LUMC
methods were applied to data from British and Italian
centres for comparison with the existing BSBMT and
GITMO systems. These two national systems were identi-
ﬁed in initial scoping as being examples of well-established
and accepted national systems within EBMT, albeit with
some weaknesses such as lack of risk adaptation. Six other
national systems were subsequently used to inform the
modelling process. Members of the CIBMTR were co-opted
into the group to relay the experience of the well-established
CIBMTR benchmarking system for allogeneic HSCT. The
goal was not to supplant existing performance evaluations
but to supplement them and to facilitate comparisons across
Europe and inform the development of a model that could
be accepted and used by EBMT centres, with uptake and
roll out driven by JACIE accreditation requirements.
One major issue recognised at an early stage was the
completeness of data within the existing EBMT data.
Experience from other benchmarking systems combined
with examinations of the EBMT database in recent years
highlighted the fundamental importance of high data com-
pleteness. Both follow-up and variables that were con-
sidered clinically relevant to risk adjustment needed to be
complete. With respect to the latter, although there was a
desire among the clinical members to incorporate modern
genetic prognostic data and a consistently reported degree
of HLA-matching data into the adjustments, it became
apparent that these and other variables were not reliably
reported in the current database and therefore would have to
be considered for future reporting via the mandatory core
dataset. Thus, to an extent, the selection of the variables for
‘ﬁrst phase’ was based on an appraisal of the available data
and subsequent consensus across the group.
Implementation and resourcing
The group discussed model methods and assumptions,
interpretation and limitations of the results, and considered
the impact of the introduction of a benchmarking system
with a process to be opened in which EBMT would decide
Contract signed Methodology
paper published
22 Feb ′19
Position paper
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26 Aug ′19
08 Mar ′18
1st quarter 1st quarter
JACIE adoption
25 May ′20
European
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Fig. 1 Timeline for projected development of clinical outcomes benchmarking process and scoping of established benchmarking systems
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how the benchmarking information should be delivered to
the centres and how centres should be supported in their
interpretation of results. Formal consultation with the EBMT
membership has been ongoing throughout the developments
to enable amendments before ﬁnalisation. This included
several updates via EBMT Newsletters and a Special Ses-
sion dedicated to Benchmarking (Special Session dedicated
to Benchmarking. https://www.ebmt.org/ebmt/news/plena
ry-and-special-sessions-ebmt-2019. Accessed 08/07/2019)
at the Annual EBMT Congress in Frankfurt in March 2019.
In tandem, the EBMT Board, Registry Committee and
JACIE Committees serially reviewed the programme at
their regular meetings and allocated resources for initial
development of modelling, testing and roll out with a view
to sustainable delivery via the JACIE Ofﬁce.
Selection of cases
The EBMT benchmarking project targets only ﬁrst auto-
logous HSCT and ﬁrst allogeneic HSCT (including those
preceded by an autologous transplant), which cover
around 80% of all transplant activity, because inclusion of
subsequent transplants complicates calculation of survival
post-transplant. In addition, for both allogeneic and
autologous HSCT, patients treated for solid tumours were
excluded. For autologous HSCT, only transplants for
adults with haematological cancers (lymphoma, myeloma,
and acute leukaemia) were included, with exclusion of
paediatric transplants (recipient <18 years old) and other
rare indications, such as autoimmune diseases, which will
be addressed at a later stage of development.
Selection of centres for benchmarking
Inclusion criteria for centres included:
● Full membership of EBMT;
● During the 4-year period 2013–2016 at least 80% of the
transplants reported in the Activity Survey for the centre
were registered in the EBMT;
Additional inclusion criteria for centres for benchmark-
ing allogeneic and autologous transplants were deﬁned as
follows based on the JACIE minimum activity thresholds:
● Allogeneic transplants: during the period 2013–2016 a
minimum of 10 allografts per year on average;
● Autologous transplants: during the period 2013–2016 a
minimum of 5 autografts per year on average
Selections were made separately for allogeneic and
autologous transplants. The 4-year time frame for selection
of centres was dictated by the availability of separately
collected activity reports. This data was used to compare
actual registrations with expected levels of activity as
reported by the centres. Future benchmarking efforts will
use a 5-year period for selection of centres.
Selection of covariates for case mix correction
The statistical goal was to develop a model comparing the
performance of all EBMT centres against a benchmark;
this benchmark is set internally by determining the per-
formance across all centres by means of a regression
model. Using such a model, it is possible to adjust for
relevant patient, disease and transplant characteristics
known to affect HSCT outcomes. This protects centres
treating difﬁcult patients from appearing to provide sub-
standard care, where poor performance may be due to the
unfavourable case mix.
The CIBMTR had previously determined a list of rele-
vant patient, disease and transplant characteristics and this
list was also incorporated, to the extent that the suggested
variables are available within the EBMT registry. Thus, the
variables that describe the case mix of allogeneic HSCT to
be used by EBMT were deﬁned as follows:
● Diagnosis (and disease status/stage)
● Donor type: matched sibling donor vs. other related vs.
unrelated donor
● Coexisting disease (HCT-speciﬁc comorbidity index,
HCT-CI)
● Recipient age
● Donor age
● Recipient and donor gender
● Recipient cytomegalovirus (CMV) serological status
● Recipient Karnofsky/Lansky Performance Status score
at transplant
● Prior autologous transplant
● Time from diagnosis to transplant for acute myelogen-
ous leukaemia (AML) and acute lymphoblastic leukae-
mia (ALL) not in CR1 or primary induction failure (PIF)
(used as surrogate for length of CR)
● Year of transplant
The same variables are used for autologous HSCT,
except coexisting disease, interval diagnosis—transplant,
recipient cytomegalovirus (CMV) serology, CR1 vs. not
CR1, prior autologous transplant (and age of donor, donor
type and biological donor gender).
Incorporating diagnosis (at transplant), disease
status/stage (at transplant): disease risk index (DRI)
Armand et al developed a DRI [19] with four categories;
Low, Intermediate, High and Very high. The EBMT have
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validated DRI in EBMT data for allogeneic HSCT [20] and
the DRI has been examined in more speciﬁc contexts.
For our ‘ﬁrst phase’ model, we started with a ‘crude’
version of the DRI which does not take cytogenetics into
account, using the exact deﬁnition of Armand et al. [19].
The DRI categories including cytogenetics were subse-
quently obtained from the EBMT registry (Myriam Labo-
pin, personal communication), using the categorisation in
Table 4, and merged into the ﬁle for the ‘ﬁrst phase’ sta-
tistical model, enabling a cross-tabulation of the DRI
without cytogenetics versus the DRI with cytogenetics. All
missing cytogenetic data for MDS and AML patients were
coded as “intermediate cytogenetic risk” [19]. This led to a
re-classiﬁcation of DRIs, especially for autologous trans-
plants, with many of the DRI’s that were classiﬁed as
intermediate being reclassiﬁed as low. Diseases not inclu-
ded in the original DRI were categorised based on similar
diseases; all non-malignant diseases were considered as low
risk. For a future benchmarking ‘second phase’ an improved
reﬁned DRI considering more detailed cytogenetic infor-
mation is to be implemented by the Leiden statistical team.
Although a substantial number of absent variables
remained, an expert consensus emerged on the need to reﬂect
the clinical importance of cytogenetics despite limited avail-
able data. Therefore, a decision was taken to develop a
‘default’ system within the ‘ﬁrst phase’model i.e. applying the
‘crude’ DRI with cytogenetics from the DRI with cytogenetics
where available from the EBMT registry ﬁle, but when
missing replaced by the ‘crude’ DRI without cytogenetics.
Outcome and data quality
To be able to make a reliable comparison of one-year sur-
vival across centres, it is essential to have adequate follow-
up. Unfortunately, the quality of follow-up differs sub-
stantially between centres. It was therefore decided to ﬁrstly
benchmark all centres on the quality of their follow-up. That
is, loss to follow-up within one year after HSCT is the
outcome of interest; death is censoring the follow-up length.
This approach is similar to the use of the reverse
Kaplan–Meier for estimating the follow-up distribution.
As loss to follow-up could hamper the benchmarking on
mortality, it was therefore decided to ﬁt benchmark models
for mortality using only the 50% centres with the best
quality of follow-up. The decision which centres have the
best follow-up is based on the p-values associated with
benchmarking follow-up.
Missing case mix data
Missing case mix data was dealt with differently when ﬁt-
ting the benchmark models and when performing the actual
Table 4 Reﬁnement of the disease risk index (DRI, derived from
Armand et al, reference 19) as applied to the ﬁrst phase of the EBMT
benchmarking system
Disease Stage DRI group
Hodgkin lymphoma CR Low
CLL CR Low
Mantle cell lymphoma CR Low
Indolent NHL CR Low
AML favourable cytogenetics CR Low
Indolent NHL PR Low
CLL PR Low
CML chronic phase 1/2 Low
CML advanced phase Int
Mantle cell lymphoma PR Int
Myeloproliferative neoplasm Any Int
AML intermediate cytogenetics CR Int
ALL CR1 Int
T-cell NHL CR Int
Multiple myeloma CR/VGPR/PR Int
Aggressive NHL CR Int
Low-risk MDS adverse cytogenetics Early† Int
T-cell NHL PR Int
Low-risk MDS intermediate cytogenetics Early† Int
Hodgkin lymphoma PR Int
Low-risk MDS intermediate cytogenetics Advanced† Int
Indolent NHL Advanced† Int
CLL Advanced Int
High-risk MDS intermediate cytogenetics Early Int
Aggressive NHL PR Int
T-cell NHL Advanced† High
AML favourable cytogenetics Advanced† High
Hodgkin lymphoma Advanced† High
High-risk MDS intermediate cytogenetics Advanced† High
High-risk MDS adverse cytogenetics Early High
ALL CR2 High
AML adverse cytogenetics CR High
Mantle cell lymphoma Advanced† High
High-risk MDS adverse cytogenetics Advanced† High
Burkitt lymphoma CR High
Multiple myeloma Advanced† High
ALL CR3 High
Low-risk MDS adverse cytogenetics Advanced† High
AML intermediate cytogenetics Advanced High
CML blast phase Very high
ALL Advanced† Very high
Aggressive NHL Advanced† Very high
AML adverse cytogenetics Advanced† Very high
Burkitt lymphoma PR Advanced† Very high
†Advanced stage refers to induction failure or active relapse, including
stable or progressive disease for NHL, HL or CLL
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benchmarking. For ﬁtting the benchmark models, multiple
imputation was used to avoid any bias due to missingness at
random. However, when doing the actual benchmarking,
missing case mix variables are imputed by their median/
mode among all patients within the EBMT with
observed favourable outcome (for benchmarking one-year
mortality this means patients that survived one year
after HSCT).
This will make the patient appear “relatively healthy”,
and lead to an unfavourable observed over expected ratio
for the centre. This should encourage centres to strive for
complete registration of case mix variables.
Benchmarking with funnel plots
The benchmark regression model can perform the following
tasks:
- Compute the expected number of unfavourable out-
comes within each centre;
-Compare this expected number to the number of
unfavourable outcomes observed;
- Perform a statistical test of the hypothesis that a centre’s
performance does not differ from the benchmark;
- Quantify the evidence for under- or over-performance of
each centre by means of the p-value of that test;
- Represent the results graphically in a so-called funnel plot
[22]. The performance of centres that fall outside of the
funnel may be considered to be signiﬁcantly different
from the benchmark at a ﬁxed level of signiﬁcance,
usually 5%.
The funnel plot has become a standard tool for centre
comparisons and is visually attractive and easy to inter-
pret. In most applications, funnel plots are based on bin-
ary outcomes. However, when benchmarking one-year
mortality the funnel plot needs to be adjusted to time-to-
event data that may be subject to censoring. While the
same principle applies, there is a need to use Cox
regression instead of logistic regression to construct the
benchmark. The full technical details of our approach are
beyond the scope of this position paper and fully descri-
bed in “Statistical use of Cox method Funnel Plots in
clinical benchmarking HSCT” (van Zwet et al.,
unpublished).
Benchmarking one-year mortality
For benchmarking one-year mortality, the expected
number of unfavourable outcomes within a centre is
obtained from calculating the probability of observing a
death before one year for each patient in the centre, under
the assumption that the survival distribution after case mix
correction is the same for all centres (this is the null-
hypothesis) while the censoring distribution may differ
between centres. If T is the event time (death) and C is the
censoring time (length of follow-up in case of no event),
then the probability of observing a death for a particular
patient in the centre within one-year equals (time is in
months)
PðT <C; T < 12jcentre; patient characteristicsÞ
¼ R
12
t¼0
P T ¼ tjpatient characteristicsð ÞP C > tjcentreð Þdt:
To compute this probability, we use a case mix-corrected
model for the distribution of T and a centre-speciﬁc model
for the distribution of C.
Benchmarking one-year loss to follow-up
For benchmarking one-year loss to follow-up, we change
the event of interest from “dead before one year” to “lost
to follow-up within one year”. So, for each patient we
compute the probability of observing the censoring
event before one year under the assumption that the
censoring distribution is the same for all centres (this is
the null hypothesis), while the survival distribution
may differ between centres. To be precise, the
probability of observing the censoring event before one-
year equals
PðC<T;C< 12jcentre; patient characteristicsÞ
¼ R
12
t¼0
P C ¼ cð ÞP T > cjcentre; patient characteristicsð Þdc:
To compute this probability, we use an uncorrected model
for the distribution of C and a centre-speciﬁc, case mix-
corrected model for the distribution of T.
In addition to visualising one-year loss to follow-up in a
funnel plot, we also quantiﬁed the completeness of follow-
up using the methods of Clark et al. [23] namely by cal-
culating for each centre the total follow-up time
P
j tij,
divided by the total maximum follow-up time
P
j t

ij. The
maximum follow-up time tij in this case is either the time of
death, if the patient dies within one year, or one year, if the
patient is alive at the end of one year [19]. Only patients
transplanted in 2013–2016 were included in this calculation.
The centres are categorised into one of three categories,
with colour coding, intended to be used as an additional
signal, next to the funnel plot:
1. Centre has very good follow-up (>90%) fulﬁlling
proposed EBMT criteria and can be included in the
benchmarking: (GREEN—compliant);
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2. Centre has a follow-up of borderline completeness
(80–90%) provisionally fulﬁlling proposed EBMT
criteria and can be included this time but needs to
improve to stay in the system: (AMBER—partially
compliant);
3. Centre has a reported follow-up of a quality not
allowing benchmarking (<80%) and are therefore
below proposed EBMT criteria which could affect
JACIE accreditation: (RED—noncompliant)
Results
Benchmarking for allogeneic HSCT
A total of 288 centres, providing data for 61,826 patients
have contributed to this benchmarking project for allogeneic
transplants.
One-year mortality
Figure 2 shows the funnel plot for one-year mortality for
allogeneic transplants. In the funnel plot of Fig. 2, each dot
represents a centre. The x-axis represents the sample size. In
the absence of case mix differences and complete one-year
follow-up this would exactly be the number of allogeneic
transplants performed in that centre over the benchmarking
period. However, the survival model was adjusted for case
mix so that it now represents an approximation of the
number of allogeneic transplants (van Zwet et al., unpub-
lished). Larger centres are more to the right, smaller ones
more to the left. The y-axis is observed/expected; this
represents the excess events (deaths within one year in this
context). A value of two means that in the benchmarking
period the number of events is twice as high as expected. Of
course, a ratio of observed/expected of two provides more
evidence of the centre not performing according to bench-
mark if that ratio is based on a larger sample size. The
funnel shaped curves represent boundaries for signiﬁcance
of the null hypothesis (the centre having the same perfor-
mance in terms of one-year mortality as the benchmark).
The funnels are wider towards the left and narrower towards
the right, reﬂecting the fact that for small centres only very
large observed/expected ratios are evidence of under-
performance, while large centres need a smaller observed/
expected ratio to provide evidence of underperformance.
Centres within the inner funnel are performing within range;
centres between the inner and outer funnels are performing
worse (upper half) or better (lower half) than average,
according to the 5% signiﬁcance level. Finally, centres
outside the outer funnel are performing worse (upper half)
or better (lower half) than average, according to a multiple-
testing adjusted signiﬁcance level of 5%; if all centres were
performing according to benchmark, then there would be a
5% probability that any of the centres were outside the outer
funnel.
One-year loss to follow-up
Figure 3 shows the funnel plot for one-year follow-up.
Clearly the variability in performance is much greater for
loss to follow-up, compared to one-year mortality. The
funnel plot in Fig. 3 compares the performance of each
centre with the benchmark, which is set internally as the
average loss to follow-up among all included centres. As
such, it is a relative comparison. A more absolute measure
of follow-up completeness is provided by the colour coding
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Fig. 2 Funnel plot for 1-year
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of the completeness of follow-up. The frequencies were
GREEN: 164 (57%), AMBER: 31 (11%), RED: 93 (32%).
Benchmarking for autologous HSCT
A total of 352 centres, providing data of 65,347 patients
have contributed to this benchmarking project for auto-
logous transplants.
Figures 4 and 5 show the funnel plots for one-year
mortality and one-year loss to follow-up, respectively, for
the autologous transplants. They were produced in the same
way as those for allogeneic transplants, but with a different
case mix model.
The colour coding of the completeness of follow-up
resulted in GREEN: 155 (44%), AMBER: 38 (11%), RED:
159 (45%).
Discussion
We have developed a ‘ﬁrst phase’ of an international
registry-based risk-adapted benchmarking system for HSCT
outcomes within EBMT, using experience of established
national systems and methodology achievable within the
EBMT registry. The system is designed to be sustainable
through future changes to the underlying technology that is
used for the EBMT registry. As a starting point, we
appraised several established national systems, both within
and outside EBMT. Although nationally accepted, the
current systems are not generally consistent or comparable
and have limitations with respect to broader application
across all EBMT members reporting to the registry.
Accommodation of case mix was variable between estab-
lished systems and generally limited. This meant no single
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system currently in use in EU countries could be easily
rolled out across EBMT. However, we were able to use the
analysis to inform the EBMT model.
How benchmarking in HSCT is implemented and sus-
tained across the many EBMT member nations and their
HSCT units will be seen over forthcoming years. The
uptake may take impetus from the need of centres to fulﬁl
FACT-JACIE 7th edition and subsequent standards, which
are likely to further reinforce the value of benchmarking.
The aim of the EBMT is to offer peer support through
JACIE with a fair, transparent and supportive system to
guide centres on possible corrective action to address any
underperformance observed through the benchmarking
mechanism. Centre anonymity needs to be maintained at
this stage of benchmarking development, but ultimately
EBMT and JACIE need to be prepared to respond in future
in case (or when) centre identiﬁcation is requested by sta-
keholders, as is the case for the CIBMTR system where
benchmarking outcomes are publicly available. National
societies, health services and regulators will also be key to
these aspects.
How do we move forward from this ‘ﬁrst phase’? The
immediate objectives are to deliver a ‘ﬁrst phase’ perfor-
mance benchmark report to all EBMT member principal
investigators to ﬁnd the position of their centre compared to
other anonymised EBMT centres for completeness of
follow-up. This is a ‘road test’ for the next and more critical
benchmark of survival outcomes. Following assurance of
data completeness, we plan to provide reports on 1-year
survival outcomes with the proviso that the system is a
work-in-progress to those centres that request it, e.g. for
preparation of JACIE. Indeed, the model was constrained
by the quality of baseline and 1-year follow-up data within
the current database. By selecting the top 50% of centres
with most complete follow-up for the 1-year survival
benchmark, we hope to drive centres to improve follow-up
reporting. Benchmarking of follow-up provides a measur-
able outcome for improvements in resourcing, clinical
supervision and education of data managers. When sus-
tainable oversight arrangements for governance have been
resourced, 1-year survival outcome performance indicators
will be made available to all centres as part of their
respective JACIE accreditation processes.
Concurrently, we plan further validation of the model
relating to DRI in autologous HSCT, and further detail
relating to histocompatibility and other risk stratiﬁcation
factors. Despite the desire of clinical expertise in the group
to include as many disease and patient-related variables as
possible that are key to transplant outcome, for example, the
lack of complete HLA-typing and genetic data meant they
had to be excluded from this ﬁrst phase model. Prospective
integration of the benchmarking process with the MACRO
registry via the mandatory core dataset will improve com-
pleteness of data reporting and form the basis for ongoing
development and sustainability of the system as an integral
part of the EBMT registry available to all member centres.
Ultimately, the MACRO database will be the sustainable
source of data, with mandatory reporting of follow-up core
data. As our understanding of prognostic data and other risk
factors improve, e.g. with the wider routine use and further
development of molecular genetics in prognosis and HLA-
matching, data collection systems in the registry will
accommodate the hierarchy of donor selection according to
disease risk [20, 21, 24, 25]. Transplant indications and
techniques also change with time, and some indications
will be of sufﬁcient size to examine speciﬁcally within
individual benchmarking exercises, leading to improved
quality and scientiﬁc insights simultaneously [24, 26, 27].
This may expand to data reporting in non-transplant treat-
ments, including CAR-T cells and other immune effector
cells [28]. Importantly, however, whilst we will plan to
incorporate additional clinical variables to ﬁne tune
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risk-adaptation within the expected capabilities of the
evolving EBMT registry, this should not compensate
for less than ideal pre-transplant decision making, e.g. with
poor patient or graft selection, or failure to recognise some
transplant modalities as investigational rather than estab-
lished procedures.
The scientiﬁc potential of benchmarking also needs to be
developed from a health economic perspective. Firstly, it is
fair to recognise that some countries in the EBMT com-
munity do not have the same resources as others,
acknowledging that macroeconomic factors have been
shown to have an impact on HSCT outcomes [29]. This will
be even more relevant as centres in low-income and middle-
income countries (LMIC) engage with FACT and JACIE
initiatives [30]. It may be possible to carefully adjust
benchmarking according to health economic indices. Sec-
ondly, the impact of benchmarking on patient survival and
other outcomes should be continually evaluated to justify
the necessary resource utilisation, not just by the EBMT and
JACIE, but also by all participating centres, data registries,
national societies and health service payers. For long-term
sustainability, there is a need for evidence of sufﬁcient
impact on patient outcomes to justify the considerable time
and resources invested. This is an ‘improvement science’
issue, similar to the exercises performed to demonstrate the
potential beneﬁts of implementation of JACIE accreditation
[14, 15, 29].
Sustainability also requires dynamic organisational and
business planning to maximise acceptance across various
national HSCT communities and run a system that can
withstand questions and even appeals from centres. A
decision was made by the EBMT Board to fund the
benchmarking out of increased JACIE fees. This is a
practical solution, but has limitations given the variable
uptake of JACIE, especially if the goal is quality
improvement across all EBMT members. Other potential
sources include EBMT membership fees; particularly as full
EBMT membership comes with a duty to report data to the
registry. All such operational aspects require ongoing
review and governance of the benchmarking system at
EBMT Board and JACIE committee levels, actioned via an
appropriately constituted and resourced oversight
committee, which will initially be comprised of clinical
members of the COG experienced in delivering bench-
marking at the national level and statistical experts, with
terms of reference and operational policies which aim to
support the EBMT membership generally and at an indi-
vidual centre level.
In summary, we have delivered the ‘ﬁrst phase’ of a
development for the EBMT. Importantly, benchmarking is
being led by the community and not by external stake-
holders who may not understand the complexities and
progress in HSCT. Inevitably there will be centres that will
have some below average results and require explanations.
There will also be some high performing centres from
which the EBMT community may learn. This is ‘work in
progress’ and the system will progressively beneﬁt from
engagement and feedback. This ‘ﬁrst phase’ should not
immediately replace national initiatives but complement
them aiming eventually to become the preferred option for
fair, user-friendly benchmarking throughout EBMT for the
beneﬁt of professionals and patients.
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